143508-41-2

Upstream product

• 6920-22-5 Hexane-1,2-diol 
• 34897-61-5 N-(benzyloxycarbonyl)-L-glutamic acid α-t-butyl ester dicyclohexylamine salt 

Downstream Products

• 143508-45-6 O^ω-<(2S,2R)-2-<<<(4S,5R)-4-(cyclohexylmethyl)-3-<(1,1-dimethylethoxy)carbonyl>-2,2-dimethyl-5-oxazolidinyl>carbonyl>oxy>hexyl>-N^α-<(phenylmethoxy)carbonyl>-L-glutamic acid, 1,1-dimethylethyl ester 
• 1054768-43-2 (6R,7S,10S)-10-Amino-3-butyl-7-cyclohexylmethyl-6-hydroxy-1,4-dioxa-8-aza-cyclotridecane-5,9,13-trione 
• 143508-48-9 (8S,11S,12R)-2-butyl-11-(cyclohexylmethyl)-12-hydroxy-8-<<(phenylmethoxy)carbonyl>amino>-5,9,13-trioxo-1,4-dioxa-10-azacyclotridecane 
• 135913-60-9 (8S,11S,12R)-2-butyl-11-(cyclohexylmethyl)-12-hydroxy-8--L-phenylalanyl>-5,9,13-trioxo-1,4-dioxa-10-azacyclotridecane 

Relevant academic research and scientific papers

Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors

Replacing one amide bond in macrocyclic renin inhibitors of the general structure 1 and 2 with an ester linkage gave glutamate-derived inhibitors 3 and serine-derived inhibitors 4.While this oxygen-for-nitrogen exchange had little effect on potency in the